Company Overview
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +29.91% |
| 6 Months: | -4.01% |
| 3 Months: | +9.57% |
| 1 Month: | +10.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)54.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IRON Disc Medicine, Inc. R2K | 75.01 | -11.30 | $2.87B | 0.00% | -30.64% | -35.83% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -9.63M | -6.67M | -7.95M | -16.49M | -16.32M | -18.45M | -9.96M | -12.02M | -10.48M | -25.12M | -17.33M | -18.96M | -31.46M | -30.85M | -32.86M | -39.95M | -61.41M | -67.70M | -69.52M |
| Net Income | -9.75M | -6.77M | -10.00M | -19.05M | -16.45M | -18.55M | -9.85M | -9.58M | -16.15M | -22.78M | -15.95M | -14.12M | -26.95M | -26.35M | -26.60M | -34.09M | -55.25M | -62.32M | -63.50M |
| Diluted EPS | - | - | - | - | -0.38 | -0.43 | -10.67 | -10.14 | -16.82 | -1.20 | -0.74 | -0.58 | -1.09 | -1.03 | -0.89 | -1.02 | -1.58 | -1.77 | -1.65 |
| R&D Expense | 8.22M | 5.53M | 6.73M | 11.79M | 10.84M | 13.46M | 7.82M | 7.71M | 7.89M | 20.18M | 12.10M | 14.42M | 23.70M | 23.48M | 24.68M | 27.76M | 46.32M | 50.33M | 45.90M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -34.04M | -30.93M | -47.48M | -91.12M | -129.72M | -236.02M |
| Net Income | -40.84M | -35.97M | -46.83M | -76.43M | -109.36M | -212.18M |
| Diluted EPS | - | -40.95 | -45.05 | -3.42 | -3.96 | -6.01 |
| R&D Expense | 28.17M | 25.17M | 33.44M | 69.26M | 96.67M | 170.64M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 8.32M | 92.41M | 200.21M | 368.00M | 496.77M | 806.88M |
| Total Equity | -10.43M | -28.81M | -64.20M | 176.60M | 345.12M | 443.59M | 739.83M |
| Cash & Equivalents | - | 4.50M | 88.04M | 194.61M | 360.38M | 192.43M | 91.14M |
| Long Term Debt | - | 14.00M | - | - | 0 | 28.32M | 29.16M |
| Total Liabilities | - | 30.18M | 14.76M | 23.61M | 22.88M | 53.19M | 67.05M |
| Current Liabilities | - | 24.88M | 13.42M | 22.58M | 21.44M | 23.32M | 36.64M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -32.71M | -27.53M | -42.25M | -73.46M | -93.93M | -180.39M |
| Investing Cash Flow | -22.00K | -68.00K | -151.00K | -89.00K | -292.33M | -394.30M |
| Financing Cash Flow | 34.25M | 89.93M | 148.98M | 239.38M | 218.31M | 473.41M |
| Capital Expenditure | -22.00K | -68.00K | -151.00K | -89.00K | -505.00K | -933.00K |
| Free Cash Flow | -32.73M | -27.60M | -42.40M | -73.55M | -94.43M | -181.33M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 141.8% | 56.0% | -26.5% | -22.1% | -24.7% | -28.7% |
| ROCE % | 205.6% | -39.2% | -26.7% | -26.3% | -27.4% | -30.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.63% | 5.59M | $417.20M |
| 2 | RA Capital Management, L.P. | 6.41% | 2.45M | $182.97M |
| 3 | Blackrock Inc. | 5.95% | 2.27M | $169.80M |
| 4 | Wellington Management Group, LLP | 4.54% | 1.74M | $129.59M |
| 5 | State Street Corporation | 4.45% | 1.70M | $126.82M |
| 6 | Price (T.Rowe) Associates Inc | 4.06% | 1.55M | $115.70M |
| 7 | Atlas Venture Life Science Advisors, LLC | 3.96% | 1.51M | $113.05M |
| 8 | Vanguard Capital Management LLC | 3.60% | 1.38M | $102.71M |
| 9 | JPMORGAN CHASE & CO | 3.59% | 1.37M | $102.42M |
| 10 | Frazier Life Sciences Management, L.P. | 3.55% | 1.35M | $101.17M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IRON
Insider Sale: Chief Executive Officer of $IRON Sells 16,896 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOcXllWVJra3FsQjJfd1RtZ2s5NGsxNUduTFgtRHRIaDZIQ3NPVl9BS1I2UW81cVMxWlF5U0xyajRDMGRUTVJUSWhydEdrLTZPOHFobGpfdDNBNmpFZ0ZWM1FNajdsRmE3NjBPSjAzODhiYjNLY1VZOG5Jc0d5MmZtWlo1OGFHU3I5aWs0Q1…
XPeng (XPEV) Stock Could Be 37% Overvalued On IRON Robot Push - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPUzFjNEoxdDJKUkVBcGJieTJNS3NoMWROXzc3R2MzcXFVaWNrTHlKLVNQdmdFelloc21oU0NNcHhOa21fRnJBenRLNXI1V3ZscVVaQUpUV3pOS3ppTDM2SjVHanBPNnUzZDVOOWRsZmxlYW1JNjBnX1hGRUY3WG5FVEJRYWdYMWhhQkZ2VV…
Best Iron Stocks of 2026 and How to Invest in Them - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPdmk5QTllcnRYYkhkU0RSYkQ2US0wZDBmeEFVQURkZEJWWGdhVFRFLUcyZDhpSndxQXB6WTE4cWJIMVJudGxleXk0S1d5Ym1fWmxVRDY3NTA0SERpUTRKNVpMQ0NudmszclFGckFYMFdGMHhDYmN3S3pIRlFqT3FKNDJpQlYwTEpfTmpnbU…
Ironwood Pharmaceuticals (NASDAQ: IRON) plans 33,000-share sale via options exercise - Stock Titan
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNbll5ajBwM3hCc2pUdjlubUZPRXVQSmU3eEpQXzYwZURlQWpJNmd1UWNmZVpmNnJqNzJPUHNRdFFNMVRaYkhad2txeG5ZQ05nSU5UY3g2S1E0Z29meFBza0x3STdBTWpxLVhsUV85WlppZDNjNmRmUHJQdVlWd2ttZFNhN0dHWHBuRlp3Tm…
Iron Dome Acquisition Corporation Rings the Nasdaq Stock Market Opening Bell - Nasdaq
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPSC1wZmtXRm9LNDBMR2FjRUhfM0x0RXB2OEdBb09HeW8tVWd3QzBIWDZ2N2h1QU44SHpJakxZTXF4Qk1EeG1JdUxaYnNmbGdNZjRVbUFKYmlPREw3YjZOVmV3R25UdTBONFIwZ2dzT1dYTENmQzYxU0Myak9oUmNfQy1WWlQ4dDZxN1JPN2…
Canadian Mining Stocks Report: Weekly Round-Up of 5 Top Performers - Investing News Network
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE1lOXdSczkwZ19VLWVZY0o3alpYS2t3Q2lxelZOUGVrQWdWNmc4cHZFSXd3d095cngtRFQ0OW5tOG1zc3pfRmhPZmVTRzVBMFlySllpb19R?oc=5" target="_blank">Canadian Mining Stocks Report: Weekly Round-Up of 5…
IRON — Frequently Asked Questions
What is the current share price of Disc Medicine, Inc. (IRON)?
As of 2026-07-14 21:23 PDT, Disc Medicine, Inc. (IRON) trades at $75.01 on NasdaqGM. Its 52-week range is $55.95 to $94.11.
What is the market capitalisation of IRON?
Disc Medicine, Inc. (IRON) has a market capitalisation of $2.87B on NasdaqGM.
What is the P/E ratio of IRON?
IRON trades at a trailing price-to-earnings (P/E) ratio of -11.30. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.77.
What is the return on equity (ROE) of IRON?
IRON has a return on equity (ROE) of -35.83%. Its return on capital employed (ROCE) is -30.64%.
Is IRON a good stock to buy?
This page provides a data-driven analysis of Disc Medicine, Inc. (IRON), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.